Long-acting (basal) insulin on SilverScript Choice (S5601-002)
Lantus, Basaglar, Tresiba and the other basal insulins, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Maine + 1 more
- Premium
- $94.90/month
- Deductible
- $615.00
1 of 7 Long-acting insulin is covered on this plan. None require prior authorization.
6 aren't on the formulary, including insulin glargine and Basaglar.
- 18%Tier 3
Not on the formulary
insulin glargine, Basaglar, Semglee, Rezvoglar, Toujeo, Tresiba
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.